Russian-Chinese intergovernmental commission discusses production, possible distribution of Sputnik V in China - RDIF
MOSCOW. Nov 26 (Interfax) - The production and possible distribution of Russia's Sputnik V and Sputnik Light coronavirus vaccines in China have been discussed at a meeting of the Russian-Chinese Intergovernmental Commission for Investment Cooperation, the Russian Direct Investment Fund (RDIF) said on Friday.
"Representatives of the Russian Direct Investment Fund (RDIF) and the Russia-China Investment Fund (RCIF) have participated in the eighth meeting of the Intergovernmental Russian-Chinese Commission for Investment Cooperation. Over the course of the meeting, the Commission members discussed investment, trade, and economic cooperation. The participants were also focused on joint efforts in the fight against coronavirus, including production and commercialization of the Russian Sputnik V and Sputnik Light vaccines in China and international markets," the RDIF said.
"On the Russian side, the commission is headed by First Deputy Prime Minister Andrei Belousov, while the Chinese side is led by Mr. Han Zheng, vice-premier of the People's Republic of China," it said.
The RDIF said in April that an agreement had been reached with the Chinese pharmaceutical company Hualan Biological Bacterin Inc. to produce over 100 million doses of the Sputnik V vaccine in China, which will be sufficient for over 50 million people.
Sputnik V has been approved in 71 countries with a total population exceeding 4 billion. It has yet to be approved for use in China.